Key terms
About NVO
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NVO news
Apr 17
2:25pm ET
Eli Lilly Stock (NYSE:LLY): Hold Off Until the End of the Month
Apr 17
6:59am ET
Novo Nordisk Executives Trade Company Shares
Apr 17
6:58am ET
Novo Nordisk Launches Major Share Buyback
Apr 16
11:10pm ET
LLY, VKTX, or NVO: Which Weight-Loss Drugmaker Could Gain the Best Returns?
Apr 15
1:34pm ET
Novo Nordisk price target raised to DKK 990 from DKK 930 at Morgan Stanley
Apr 12
12:53pm ET
LLY, NVO: Obesity Drugs May Help with Parkinson’s
Apr 12
4:47am ET
Novo Nordisk initiated with an Outperform at BMO Capital
Apr 12
4:25am ET
Buy Rating for Novo Nordisk: Strong Growth Potential Driven by Strategic Partnerships and Innovative Pipeline
Apr 08
11:57am ET
Novo Nordisk Launches Major Share Buyback
Apr 05
12:40pm ET
Viking Therapeutics Stock (NASDAQ:VKTX): Analysts Stay Bullish on 2024’s Top Mid-Cap
Apr 02
8:27am ET
Novo Nordisk Initiates Multi-Billion Share Buyback
Apr 01
1:57pm ET
Novo Nordisk Launches Multi-Billion Share Buyback
Mar 31
6:52pm ET
Omega Therapeutics price target lowered to $7 from $12 at Chardan
Mar 28
10:39am ET
Novo Nordisk Under Fire, Post-Ozempic Study
Mar 27
12:58pm ET
Ozempic manufacturing costs could be 89c per month, study finds
Mar 25
11:27am ET
Novo Nordisk Updates Corporate Governance
Mar 25
6:10am ET
Novo Nordisk to acquire Cardior Pharmaceuticals for up to EUR 1.025B
Mar 22
7:30am ET
Argus cuts Pfizer to Hold on headwinds to revenue growth
Mar 22
7:00am ET
Novo Nordisk’s Awiqli® Set to Transform Diabetes Care
Mar 21
1:27pm ET
Novo Nordisk Thrives with Record Patient Reach
Mar 21
11:58am ET
Novo Nordisk receives positive CHMP opinion on Awiqli for diabetes
Mar 21
11:00am ET
Medicare Part D may cover Novo obesity drug, WSJ reports
Mar 20
12:34pm ET
CBO analyst comments on obesity drugs similar to October 2023 report
Mar 20
12:24pm ET
Eli Lilly, Novo Nordisk lower after CBO analyst comments on obesity drugs
Mar 20
12:20pm ET
Lilly, Novo lower after CBO analyst says obesity drugs could raise deficit
Mar 20
6:20am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 18
2:52pm ET
Novo Nordisk price target raised to DKK 900 from DKK 850 at Berenberg
Mar 18
12:27pm ET
Novo Nordisk Advances Share Buyback Program
Mar 18
10:41am ET
Oprah to host TV special discussing weight loss, CNN reports
Mar 15
4:47pm ET
Eli Lilly’s (NYSE:LLY) Weight-Loss Drug Outshines Wegovy for First Time
Mar 15
4:55am ET
Piper Sandler healthcare/pharma analysts hold analyst/industry conference call
No recent press releases are available for NVO
NVO Financials
Key terms
Ad Feedback
NVO Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NVO Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range